Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 vs TAS-102 in Refractory mCRC with Acquired Anti-EGFR Resistance
NCT03717038Phase 3Withdrawn
- Sponsor
- Symphogen
- Start
- Feb 2019
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 3 trial of futuximab + modotuximab in colorectal cancer (CRC), sponsored by Symphogen. Planned start Feb 2019; status: withdrawn.
02
Drugs
futuximab + modotuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03717038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717038.